# FDA 483 - Corey G. Anderson, M.D. - September 19, 2025

Source: https://www.keypedia.com/records/483/corey-g-anderson-md/28d82723-84b8-4ae7-bb84-677b93095ef5

> FDA 483 for Corey G. Anderson, M.D. on September 19, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Corey G. Anderson, M.D.
- Inspection Date: 2025-09-19
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: Corey G. Anderson, M.D. in Tempe, AZ, was inspected and cited for significant deficiencies in clinical trial conduct. The inspection revealed failures in reporting both serious and non-serious adverse events to the sponsor, conducting the investigation according to the protocol, and maintaining adequate case histories for biological samples. These issues indicate a lack of adherence to study protocols and proper record-keeping practices.

## Related Officers

- [investigator](https://www.keypedia.com/people/dina-a-tallman/e9bf2b98-6697-4d7c-9052-84339536acfd)

Company: https://www.keypedia.com/companies/corey-g-anderson-md/a4e1398f-d75f-4df2-a4a1-567d96132e60

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6